Second trimester prenatal screening for Down's syndrome using alpha-fetoprotein and free beta hCG: A seven year review

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 106, Issue 12, 1999, Pages 1287-1293

  Spencer, Kevin ^a  

^a HAROLD WOOD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; MARKER; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; AMNIOCENTESIS; ARTICLE; DEVICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DOWN SYNDROME; FEMALE; FETUS; FETUS DEATH; FETUS DISEASE; FETUS WASTAGE; FOLLOW UP; HIGH RISK PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; NECK; OUTCOMES RESEARCH; PRENATAL CARE; PRENATAL SCREENING; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; SCREENING; SECOND TRIMESTER PREGNANCY; TRISOMY 18; TRISOMY 21;

ADULT; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FEMALE; GESTATIONAL AGE; HUMANS; MATERNAL AGE; MIDDLE AGED; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 0032785796     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1999.tb08183.x     Document Type: Article

References (29)

1. Ayme S. French decree. Down Screening News 1997; 4: 11.
2. Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down's syndrome. J Med Screen 1997; 4: 181–246.
3. Macri JN, Spencer K. Towards the optimal protocol for Down's syndrome screening. Am J Obstet Gynecol 1996; 174: 1668–1669.
4. Seth J, Sturgeon CM, Ellis AR, Al-Sadie R, Logan M. UKNEQAS for Peptide Hormones & Related Substances; Annual Review 1997. Edinburgh, 1998: 58.
5. Spencer K, Carpenter P. Prospective study of prenatal screening for Down's syndrome with free beta human chorionic gonadotrophin. BMJ 1993; 307: 764–769.
6. Spencer K. Evaluation of an assay of the free beta subunit of human choriogonadotrophin and its potential value in screening for Down's syndrome. Clin Chem 1991; 37: 809–814.
7. Spencer K, Souter V, Tul N, Snijders R, Nicoladies KH. A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free beta hCG, PAPP–A. Ultrasound Obstet Gynecol 1999; 13: 231–237.
8. Spencer K, Carpenter P. Screening for Down's syndrome using serum alpha fetoprotein: a retrospective study indicating caution. BMJ 1984; 290: 1940–1943.
9. Spencer K, Coombes EJ, Mallard AS, Milford Ward A. Free beta human choriogonadotropin in Down's syndrome screening: a multicentre study of its role compared with other biochemical markers. Ann Clin Biochem 1992; 29: 506–518.
10. Watt HC, Wald NJ. Alternative methods of maternal weight adjustment in maternal serum screening for Down syndrome and neural tube defects. Prenut Diagn 1998; 18: 842–845.
11. Wald NJ, Cuckle HS, Densem JW, Stone RB. Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in pregnancies with insulin–dependent diabetes: implications for screening for Down's syndrome. Br J Obstet Gynaecol 1992; 99: 51–53.
12. Spencer K, Salonen R, Muller F. Down's syndrome screening in multiple pregnancies using alpha fetoprotein and free beta hCG. Prenat Diagn 1994; 14: 537–542.
13. Reynolds TM, Penney MD. The mathematical basis of multivariate risk screening with special reference to screening for Down's syndrome associated pregnancy. Ann Clin Biochem 1990; 27: 452–458.
14. Cuckle HS, Wald NJ, Thompson SG. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha fetoprotein level. Br J Obstet Gynaecol 1987; 94: 387–402.
15. Spencer K, Wallace E, Ritoe S. Second trimester dimeric inhibin A in pregnancies affected by Down's syndrome. Prenar Diagn 1996; 16: 1101–1110.
16. Spencer K, Mallard AS, Coombes EJ, Macri JN. Prenatal screening for trisomy 18 with free beta hCG as a marker. BMJ 1993; 307:1455–1458.
17. Spencer K. Biochemical screening for neural tube defects and chromosomal abnormalities. The Diplomate 1997; 4: 38–43.
18. Mutton D, Ide RG, Alberman E. Trends in prenatal screening for and diagnosis of Down's syndrome: England and Wales, 1989–1997. BMJ 1998; 922–923.
19. Office for National Statistics. 1996 Birth statistics, Series FM1 no. 25. London : HMSO, 1998.
20. Spencer K, Macri JN, Anderson RV et al. Dual analyte immunoassay in neural tube defect and Down's syndrome screening: results of a multicentre clinical trial. Ann Clin Biochem 1992; 30: 394–401.
21. Spencer K. The influence of smoking on maternal serum alpha–feto–protein, free beta hCG levels and the impact on screening for Down's syndrome. Prenat Diagn 1998; 18: 225–234.
22. Verdin SM, Braithwaite JM. Spencer K, Economides DL. Prenatal diagnosis of trisomy 21 in monozygotic twins with increased nuchal translucency and abnormal serum biochemistry. Fetal Diagn Ther 1997; 12: 153–155.
23. Palomaki GE, Neveux LM, Haddow JE. Can reliable Down's syndrome detection rates be determined from prenatal screening intervention trials J Med Screen 1996; 3: 12–17.
24. Bray IC, Wright DE. Estimating the spontaneous loss of Down syndrome fetuses between the times of chorionic villus sampling, amniocentesis and live birth. Prenat Diagn 1998; 18: 1045–1054.
25. Macri JN, Spencer K, Garver K et al. Maternal serum free beta Down syndrome screening: Results of twelve studies including 480 cases of Down syndrome. Prenat Diagn 1994; 14: 97–103.
26. Spencer K. The accuracy of Down's syndrome risk produced in a prenatal screening program. Ann Clin Biochem 1999; 35: 101–103.
27. Goshen R. The genomic basis of the beta subunit of human chorionic gonadotropin diversity in triploidy. Am J Obstet Gynecol 1994; 170: 700–701.
28. Eiben B, Hammans W, Goebel R. Triploidy, imprinting and hCG levels in maternal serum screening. Prenat Diugn 1996; 16: 377–378.
29. Wald NJ, Kenard A, Densem JW, Cuckle HS, Chard T, Butler L. Antenatal maternal serum screening for Down's syndrome: results of a demonstration project. BMJ 1992; 305: 391–394.